Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 open-label study of KRT-232 plus ruxolitinib in myelofibrosis with suboptimal response to ruxolitinib
MOH_2021-11-16_010407Phase 2Completed
- Sponsor
- Kartos Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of navtemadlin and ruxolitinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by Kartos Therapeutics. Started Nov 2021; status: completed.
02
Drugs
navtemadlinruxolitinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on MOH_2021-11-16_010407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-16_010407.